ClearPoint Neuro to Announce First Quarter 2024 Results May 7, 2024
24 April 2024 - 6:05AM
ClearPoint Neuro, Inc. (Nasdaq: CLPT) (the “Company”), a global
device, cell, and gene therapy-enabling company offering precise
navigation to the brain and spine, today announced that it will
release financial results for its 2024 first quarter on Tuesday,
May 7th, after the market close.
Investors and analysts are invited to listen to
the live broadcast review of the Company’s 2024 first quarter on
Tuesday, May 7th, at 4:30 p.m. Eastern time (1:30 p.m. Pacific
time) which may be accessed online here. Investors and analysts who
would like to participate in the conference call via telephone may
do so at (877) 407-9034, or at (201) 493-6737, if calling from
outside the U.S. or Canada.
For those who cannot access the live broadcast,
a replay will be available shortly after the completion of the call
until June 7, 2024, by calling (877) 660-6853 or (201) 612-7415, if
calling from outside the U.S. or Canada, and then entering
conference I.D. number 413671. An online archive of the broadcast
will be available on the Company’s Investor website at
https://ir.clearpointneuro.com
About ClearPoint Neuro
ClearPoint Neuro is a device, cell, and gene
therapy-enabling company offering precise navigation to the brain
and spine. The Company uniquely provides both established clinical
products as well as pre-clinical development services for
controlled drug and device delivery. The Company’s flagship
product, the ClearPoint Neuro Navigation System, has FDA clearance
and is CE-marked. ClearPoint Neuro is engaged with healthcare and
research centers in North America, Europe, Asia, and South America.
The Company is also partnered with the most innovative
pharmaceutical/biotech companies, academic centers, and contract
research organizations, providing solutions for direct CNS delivery
of therapeutics in pre-clinical studies and clinical trials
worldwide. To date, thousands of procedures have been performed and
supported by the Company’s field-based clinical specialist team,
which offers support and services to our customers and partners
worldwide. For more information, please visit
www.clearpointneuro.com.
Forward-Looking Statements
Statements in this press release and in the
teleconference referenced above concerning the Company’s plans,
growth and strategies may include forward-looking statements within
the context of the federal securities laws. Statements regarding
the Company's future events, developments and future performance,
the size of total addressable markets or the market opportunity for
the Company’s products and services, the Company’s expectation for
revenues, operating expenses, the adequacy of cash and cash
equivalent balances to support operations and meet future
obligations, as well as management's expectations, beliefs, plans,
estimates or projections relating to the future, are
forward-looking statements within the meaning of these laws. These
forward-looking statements are based on management’s current
expectations and are subject to the risks inherent in the business,
which may cause the Company's actual results to differ materially
from those expressed in or implied by forward-looking statements.
Particular uncertainties and risks include those relating to:
global and political instability, supply chain disruptions, labor
shortages, and macroeconomic and inflationary conditions; future
revenue from sales of the Company’s products and services; the
Company’s ability to market, commercialize and achieve broader
market acceptance for new products and services offered by the
Company; the ability of our biologics and drug delivery partners to
achieve commercial success, including their use of the Company’s
products and services in their delivery of therapies; the Company’s
expectations, projections and estimates regarding expenses, future
revenue, capital requirements, and the availability of and the need
for additional financing; the Company’s ability to obtain
additional funding to support its research and development
programs; the ability of the Company to manage the growth of its
business; the Company’s ability to attract and retain its key
employees; and risks inherent in the research, development, and
regulatory approval of new products. More detailed information on
these and additional factors that could affect the Company’s actual
results are described in the “Risk Factors” section of the
Company’s Annual Report on Form 10-K for the year ended December
31, 2023, which has been filed with the Securities and Exchange
Commission, and the Company’s Quarterly Report on Form 10-Q for the
three months ended March 31, 2024, which the Company intends to
file with the Securities and Exchange Commission on or before May
15, 2024. The Company does not assume any obligation to update
these forward-looking statements.
Contact:
Media Contact:
Jacqueline Keller, Vice President of Marketing
(888) 287-9109 ext. 4
info@clearpointneuro.com
Investor Relations:
Danilo D’Alessandro, Chief Financial Officer
(888) 287-9109 ext. 3
ir@clearpointneuro.com
ClearPoint Neuro (NASDAQ:CLPT)
Historical Stock Chart
From Apr 2024 to May 2024
ClearPoint Neuro (NASDAQ:CLPT)
Historical Stock Chart
From May 2023 to May 2024